Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares 31-05-2024, 13:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Zoom Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025 18-03-2025, 18:30